Psilocybin in Participants with Treatment Resistant Depression (P-TRD)

• Research type

  Research Study

• Full title

  The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)

• Contact name

  Susan C. Stansfield

• Contact email

  sue@compasspathways.com

• Sponsor organisation

  COMPASS Pathways, Ltd

• Eudract number

  2017-003288-36

• Duration of Study in the UK

  1 years, 4 months, 30 days

• Research summary

  A recent open label study of the effects of psilocybin in participants with treatment resistant depression (TRD) showed rapid significant decrease of depressive symptoms after treatment with psilocybin coupled with psychological support. Over 40% of participants sustained response at 3 months. In this study, the aim is to assess effectiveness of 3 different doses of psilocybin (1 mg, 10 mg, and 25 mg) in TRD, with the lowest dose assumed to be in effect a placebo.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  17/LO/1889

• Date of REC Opinion

  31 Jan 2018

• REC opinion

  Further Information Unfavourable Opinion